BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Category: Business
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its th…
IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK–(BUSINESS WIRE)–IVERIC bio reported that on Nov. 1, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of common stock.
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
DUBLIN–(BUSINESS WIRE)–Horizon announced that clinical data for teprotumumab in the treatment of active thyroid eye disease will be presented at the ACR Annual Meeting.
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of…
NovaBay Pharmaceuticals Launches Online Sales of CelleRx® Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures
EMERYVILLE, Calif.–(BUSINESS WIRE)– #NovaBay–NovaBay Pharmaceuticals launches online sales of CelleRx skin cleanser for post-aesthetic dermatology and cosmetic procedures
Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial resu…
EMA und FDA nehmen Zulassungsanträge für Satralizumab gegen Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) von Chugai entgegen
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), hat bekannt gegeben, dass die Europäische Arzneimittel-Agentur (EMA) den Zulassungsantrag für Satralizumab (Entwicklungscode: SA237), einen humanisierten, rezyklierenden Interleukin…
Glaukos Announces Participation in Stephens Investor Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical methods trial of to…
Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program
CRANBURY, N.J.–(BUSINESS WIRE)– #AAO2019–Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program
Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
HTL investit dans des capacités de production GMP pour soutenir un marché des applications médicales de l’Acide Hyaluronique en forte croissance.
JAVENÉ, France–(BUSINESS WIRE)–HTL, leader mondial de la production d’Acide Hyaluronique et d’autres biopolymères, annonce qu’il investit dans une unité de production à la pointe de la technologie, qui multipliera par 2,5 sa capacité de production de…
HTL invests in GMP manufacturing capacity to support fast growing market of Hyaluronic Acid Medical Applications
JAVENÉ, France–(BUSINESS WIRE)– #hyaluronicacid–HTL Biotechnology invests in GMP manufacturing capacity to support the fast growing market of medical applications for Hyaluronic Acid.
Riassunto: EMA e FDA accettano le richieste di autorizzazione alla commercializzazione per satralizumab nel trattamento del disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha annunciato che l’Agenzia europea per i medicinali (European Medicines Agency, EMA) ha accettato le richieste di autorizzazione alla commercializzazione per satralizumab (codice di…
EMA and FDA Accept Marketing Applications for Chugai's Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)– #NMOSD–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab (development code: SA237), an anti-interleukin-6 (IL…